Methyl 5-(4-piperidyl)pentanoate | 1305383-46-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Methyl 5-(4-piperidyl)pentanoate
• 英文别名: methyl 5-piperidin-4-ylpentanoate
• CAS: 1305383-46-3
• 化学式: C₁₁H₂₁NO₂
• 分子量: 199.293
• InChiKey: DSNOTBJUKIBYQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲醇 、 Methyl 5-(4-piperidyl)pentanoate 在 potassium hydrogensulfate 作用下， 以 sodium hydroxide 为溶剂， 生成 5-(1-t-Butoxycarbonyl-4-piperidyl)pentanoic acid
  参考文献：
  名称：

  Fibrinogen receptor antagonists

  摘要：

  本发明揭示了一种公式为：##STR1##的纤维蛋白原受体拮抗剂，用于抑制纤维蛋白原与血小板的结合以及抑制血小板的聚集。

  公开号：

  US05264420A1
• 作为产物：
  描述：

  甲醇 、 5-(4-哌啶基)戊酸 在 氯化亚砜 作用下， 生成 Methyl 5-(4-piperidyl)pentanoate
  参考文献：
  名称：

  Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors

  摘要：

  We report here the strategy used in our research group to find a new class of histone deacetylase (HDAC) inhibitors.A series of N-substituted 4-alkylpiperazine and 4-alkylpiperidine hydroxamic acids, corresponding to the basic structure of HDAC inhibitors (zinc binding moiety-linker-capping group) has been designed, prepared, and tested for HDAC inhibition.Linker length and aromatic capping group connection were systematically varied to find the optimal geometric parameters. A new series of submicromolar inhibitors was thus identified, which showed antiproliferative activity on HCT-116 colon carcinoma cells. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.085

文献信息

• US5264420A
  申请人：——

  公开号：US5264420A

  公开（公告）日：1993-11-23
• [EN] TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE<br/>[FR] COMPOSÉS CIBLANT LA PROTÉINE TAU ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：ARVINAS OPERATIONS INC

  公开号：WO2021011913A1

  公开（公告）日：2021-01-21

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tan protein, such that tan protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tan. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tan protein. Diseases or disorders that result from aggregation or accumulation of tan protein are treated or prevented with compounds and compositions of the present disclosure.
• Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors
  作者：Cristina Rossi、Marina Porcelloni、Piero D’Andrea、Christopher I. Fincham、Alessandro Ettorre、Sandro Mauro、Antonella Squarcia、Mario Bigioni、Massimo Parlani、Federica Nardelli、Monica Binaschi、Carlo A. Maggi、Daniela Fattori

  DOI：10.1016/j.bmcl.2011.02.085

  日期：2011.4

  We report here the strategy used in our research group to find a new class of histone deacetylase (HDAC) inhibitors.A series of N-substituted 4-alkylpiperazine and 4-alkylpiperidine hydroxamic acids, corresponding to the basic structure of HDAC inhibitors (zinc binding moiety-linker-capping group) has been designed, prepared, and tested for HDAC inhibition.Linker length and aromatic capping group connection were systematically varied to find the optimal geometric parameters. A new series of submicromolar inhibitors was thus identified, which showed antiproliferative activity on HCT-116 colon carcinoma cells. (C) 2011 Elsevier Ltd. All rights reserved.
• Fibrinogen receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US05264420A1

  公开（公告）日：1993-11-23

  Fibrinogen receptor antagonists of the formula: ##STR1## are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.

  本发明揭示了一种公式为：##STR1##的纤维蛋白原受体拮抗剂，用于抑制纤维蛋白原与血小板的结合以及抑制血小板的聚集。